Instituto Hermes Pardini S A : Dados Econômico-Financeiros

s

QUARTERLY INFORMATION 3Q21

ntents
Earnings Release ...................................................................................................................................	3
Summary
Results Release ..............................................................................................................................................	3
Quarterly Information
Report on review of Interim Financial Information (ITR).............................................................................	16
Statement of financial position....................................................................................................................	18
Statement of income ...................................................................................................................................	19
Statement of comprehensive income..........................................................................................................	21
Statement of changes in equity ...................................................................................................................	22
Statement of cash flows ..............................................................................................................................	23
Statement of value added............................................................................................................................	24
Notes to the financial statements ...............................................................................................................	25
1	Operations............................................................................................................................................	25
2	Basis of preparation and presentation of the interim financial information, and a summary of
	significant accounting practices ...........................................................................................................	27
3	Business combination ..........................................................................................................................	29
4	Cash and cash equivalents and financial investments .........................................................................	32
5	Trade receivables .................................................................................................................................	32
6	Inventories ...........................................................................................................................................	33
7	Taxes recoverable ................................................................................................................................	33
8	Other assets .........................................................................................................................................	34
9	Investments..........................................................................................................................................	35
10	Property and equipment......................................................................................................................	36
11	Intangible assets...................................................................................................................................	37
12	Right-of-use assets ...............................................................................................................................	39
13	Trade payables .....................................................................................................................................	41
14	Tax, social security and labor obligations ............................................................................................	41
15	Leases ...................................................................................................................................................	42
16	Debentures and borrowings ................................................................................................................	43
17	Taxes payable in installments ..............................................................................................................	44
18	Provision for contingencies..................................................................................................................	45
19	Current and deferred income tax and social contribution ..................................................................	46
20	Restricted financial investments and payables for acquisition of investments...................................	49
21	Equity ...................................................................................................................................................	51
22	Net service revenue .............................................................................................................................	52
23	Operating costs and expenses by nature.............................................................................................	53
24	Finance income (costs).........................................................................................................................	55
25	Related-party transactions...................................................................................................................	56
26	Earnings per share................................................................................................................................	59
27	Financial instruments and risk management.......................................................................................	60
28	Non-cash transactions..........................................................................................................................	63
Officers' Statement on the Quarterly Information......................................................................................	65
Officers' Statement on the Independent Auditor's Review Report.............................................................	66

Medicine, Health and Well-Being

EARNINGS RELEASE

3

Record Test Processing

Belo Horizonte, November 10, 2021 - Instituto Hermes Pardini S.A. ("IHP"), one of Brazil's largest Diagnostic Medicine companies,

announces its operating and financial results for the third quarter of 2021 (3Q21). Except where stated otherwise, information in this document is provided in local currency (Reais). The consolidated quarterly information of the Company is prepared in accordance with the accounting practices adopted in Brazil, based on the Brazilian Corporation Law and CVM regulations, as well as International Accounting Standard (IAS) 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB).

1

3Q21 Highlights

RECORD

Number of tests	Gross Margin	Net Income
37.3 million	31.7%	R$52.7 million

Gross Revenue	EBITDA	Net Margin
R$548.3 million	R$121.6 million	10.4%

Gross Profit	EBITDA margin	ROIC without
R$160.8 million	24.0%	goodwill
		47.2%
	Operating Cash Flow
	R$121.2 million

4

2 Message from the Management

The Pardini Group presents its results for the third quarter of 2021. We once again achieved record numbers, processing over 37.3 million tests during the period, thanks to the

technical stability of the enterprise model, which also reduced the TAT for test results. Compared to the third quarter in previous years, we set record test numbers, revenue, gross profit and EBITDA in 3Q21.

Gross revenue came to R$548 million in the quarter, a double-digit growth over our budget and our second highest quarterly result, coming only behind 2Q21 when toxicology tests registered significant growth. Revenue from COVID-19 tests came to R$85 million in 3Q21, driven by the acquisitions of the Paulo Azevedo and APC laboratories.

The quarter was marked by the full effects of the positive contribution from price changes under the Lab-to-Lab (L2L) system launched in March.

Production costs were maintained within our budget. The improved performance was due to higher

absorption of fixed costs and the percentage increase in salary below inflation (IPCA index), resulting in EBITDA of R$121.6 million (margin

of 24.0%) in the quarter.

EXPANSION OF FOOTPRINT IN SÃO PAULO

Following the IRV acquisition of APC

• Laboratório de Anatomia Patológica on August 2, we were selected, in an open bidding process, by a major health plan as their exclusive provider of diagnostic medicine services for around 700,000 beneficiaries in the city of São Paulo and the metropolitan region. Since October, the five Hermes Pardini units in São
  Paulo have been conducting clinical tests, as well as anatomic pathology and imaging tests for such beneficiaries, serving them gradually. To honor this agreement, in addition to the Moema Unit, which will be opened in November, more five new units in the coming months will be inaugurated in São
  Paulo and the metropolitan region.

PATIENT

SERVICE CENTERS (PSC)

In 3Q21, total gross revenue from Patient Service Centers (PSC) grew 26% compared to 3Q20. Excluding COVID-19 tests, growth was 33%. Compared to 3Q19 (pre- pandemic period), total PSC gross revenue increased 50%. Excluding COVID-19 tests, growth stood at 24%. Volume grew throughout the quarter across all Company locations except Rio de Janeiro. In 3Q21, imaging exams posted double- digit growth compared to 3Q20 at all Company locations.

Higher volumes absorbed costs and EBITDA from PSC in 3Q21 registered double-digit growth in relation to both 3Q20 and 3Q19. We opened our first Premium Store in Goiás. The Portugal Unit was renovated and elected by the Pardini Group to offer a fresh experience in Diagnostic Medicine to our customers. We will have a more robust structure but which retains important differentials such as the room for tests at rest, pediatric test room and Wi-Fi, now in a more spacious, cozy and modern environment, as well as offers valet parking, bilingual receptionist

and special breakfast.

In 3Q21, we developed a comprehensive flow of confirmations for imaging exams via text messages, voice messages and WhatsApp to ensure more effective confirmations, reduce the no-show rate

and better utilization of schedules, achieving 90% customer return. We further improved our online imaging scheduling platform, with the number of scheduled tests growing 15% in 3Q21 compared to 3Q20. In 3Q21, we

maintained the 25% rate of retention in bots due to the evolution of digital tools (WhatsApp, IVR and app). For house calls, we continued to replicate our management and service model across all Pardini Group companies and also added rapid COVID-19 tests at all our units to meet the growing demand caused by the resumption of social events. We are proud to announce that our diagnostic imaging services are now accredited by the Diagnostic Imaging Accreditation Program (PADI). Developed by the Brazilian College of Radiology, whose processes are always aligned with the latest scientific and technological developments, the program

evaluates the technical expertise and the quality management system of the service offered.

5